Serum sialic acid in malignant melanoma patients: An ROC curve analysis

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3619-3622

  Ros Bullón, María Rosa ^b   Sánchez Pedreño, Paloma ^b   Martínez Liarte, José Hilario ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b Universidad de Murcia ^*

Author keywords

Melanoma; ROC analysis; Sialic acid; Tumor markers

Indexed keywords

SIALIC ACID;

AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

CASE-CONTROL STUDIES; HUMANS; MELANOMA; N-ACETYLNEURAMINIC ACID; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS;

EID: 0343114485     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Virji MA, Mercer DW, Heberman RB: Tumor markers in cancer diagnosis and prognosis.CA-Cancer J Clin 38: 104-126, 1988.
2. Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer 51: 840-843, 1983.
3. Cooper EH: Neuron-specific enolase. Int J Biol Markers 9: 205-210, 1994.
4. Deffuant C, Celerier P, Boiteau, HL, Litoux P, Dreno B: Serum Selenium in melanoma and epidermotropic cutaneous T-cell lymphoma. Acta Dermatol Venereol (Stockh) 74: 90-92, 1994.
5. Picardo M, Grammatico P, Roccella M, Grandinetti M, Del Porto G, Passi S: Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 107: 322-326, 1996.
6. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73: 629-636, 1994.
7. Hara H, Walsh N, Yamada K, Jimbow K: High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxy-indole-2-carboxylic acid as a prognostic marker for malignant melanoma. J Invest Dermatol 102: 501-505, 1994.
8. Kärnell R, von Schoultz E, Hansson O, Nilsson B, Arstrand K, Kagedal B: S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 7: 393-399, 1997.
9. Ros-Bullón MR, Sánchez-Pedreño P, Martínez-Liarte JH: Serum zinc levels are increased in melanoma patients. Melanoma Res 8: 273-277, 1998.
10. Ros-Bullón MR, Sánchez-Pedreño P, Martínez-Liarte JH: Serum tyrosine hydroxylase activity is increased in melanoma patients. An ROC curve analysis. Cancer Lett 129: 151-155, 1998.
11. Hirai S, Kageshita T, Kimura T, Tsujisaki M, Imai K, Wakamatsu K, Ito S, Ono T: Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 7: 58-62, 1997.
12. Schauer R: Characterization of Sialic Acids. In: Methods in Enzymology (Ginsburg V, ed): New York, Academic Press, vol L, 1978, pp 64-89.
13. Winzler RJ: Determination of serum glycoproteins. Methods Biochem Anal 2: 279-311, 1958.
14. Schutter EMJ, Visser JJ, van Kamp GJ, Mensdorff-Pouilly S, van Dijk W, Hilgers J, Kenemans P: The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. Tumor Biol 13: 121-132, 1992.
15. Silver HKB, Rangel DM, Morton DL: Serum sialic acid elevations in malignant melanoma patients. Cancer 41: 1497-1499, 1978.
16. Reintgen DS, Tso CY, Seigler HF: Prognosis for recurrent stage 1 malignant melanoma. Arch Surg 122: 1338-1344, 1987.
17. Matous B, Ciganek EF, Budensiská A, Duchon J: Biochemical markers of malignant melanoma. Neoplasma 34: 77-84, 1987.
18. Portoukalian J, Zwingelstein G, Abdul-Malek N, Dore JF: Alteration of gangliosides in plasma and red cells of human bearing melanoma tumors. Biochem Biophys Res Commun 85: 916-920, 1978.
19. Rorsman H, Pavel S: Metabolic markers and melanoma; in Cutaneous Melanoma, Biology and Management. Cascinelli N, Santinami M, Veronesi U (eds.) Masson, Milan pp 79-90, 1990.
20. Katopodis N, Hirshaut Y, Geller NL, Stock CC: Lipid-associated sialic acid test for the detection of human cancer. Cancer Res 45: 5270-5276, 1982.
21. Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ: The evaluation of putative tumor markers for malignant melanoma. Ann Plast Surg 28: 55-59, 1992.
22. Buzaid AC, Sandler AB, Hayden CL, Scinto J, Poo WJ, Clark MB, Hotchkiss S: Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int J Biol Markers 9: 247-250, 1994.
23. Herrmann WP, Gielen W: Sialyltransferase levels and sialic acid concentrations in sera of patients with malignant melanomas. Arch Derm Res 265: 321-329, 1979.
24. Ryan AH, Fennelly JJ: Serum sialic acid concentrations in malignant melanoma. Eur J Cancer Clin Oncol 17: 843-844, 1981.
25. Vedralová E, Borovansky J: Evaluation of serum sialic acid fractions as markers for malignant melanoma. Cancer Lett 78: 171-175, 1994.
26. American Joint Committee Cancer. Manual for staging of Cancer, ed 3. (Lippincott JB, ed), Philadelphia, 1988, pp 143-148.
27. Clark WH Jr, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr, Reed RJ: The developmental biology of primary human malignant melanomas. Semin Oncol 2: 83-103, 1975.
28. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902-908, 1979.
29. Sugahara K, Sugimoto K, Nomura O, Usui T: Enzymatic assay of serum sialic acid. Clin Chim Acta 108: 493-498, 1980.
30. Schoonjans F, Zalata A, Depuydt CE, Comhaire, FH: MedCalc: a new computer program for medical statistics. Computer Methods Programs Biomed 48; 257-262, 1995.
31. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 8: 283-298, 1978.
32. Zweigh MH, Campbell G: Receiver-operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-577, 1993.
33. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
34. MacBeth RAL, Bekasi JG: Plasma glycoproteins in various disease states including carcinoma. Cancer Res 22: 1170-1175, 1962.
35. Raynes JG: Serum concentrations of lipid bound sialic acid and acute phase proteins in patients with cancer and nonmalignant disease. Biomed Pharmacother 37: 136-138, 1983.